<DOC>
	<DOCNO>NCT02016742</DOCNO>
	<brief_summary>The purpose study characterise pharmacokinetics , safety tolerability RDC5 give single dose healthy volunteer number different dose level</brief_summary>
	<brief_title>A Phase 1 Study Pharmacokinetics RDC5 Healthy Volunteers</brief_title>
	<detailed_description>This open-label , randomise , single dose , 3-way crossover study characterise compare PK , safety tolerability RDC5 15 healthy male volunteer . Eligible subject undergo 3 Treatment Periods , separate washout period least 14 day . Subjects receive single dose RDC5 three Treatment Periods line randomize treatment sequence . A total 4 dose level evaluate within study , though subject receive 3 dos . A Data Review Team ( DRT ) review pharmacokinetic ( PK ) data Treatment Periods 1 2 select dos evaluate Treatment Periods 2 3 . Subjects return follow visit 21 day last dose RDC5 .</detailed_description>
	<criteria>Willing use effective method contraception Non smoker exsmoker within previous 6 month History presence clinically significant finding upon screen Participation New Chemical Entity clinical study within previous 124 day market drug clinical study within previous 93 day Positive result human immunodeficiency virus ( HIV ) and/or hepatitis B C test Positive result urine alcohol drug screen Blood donation â‰¥ 450 mL previous 12 week Receipt prescription medicine and/or St John 's Wort previous 2 week</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Pharmacokinetics</keyword>
</DOC>